Thus, a prediction of the current studies is that the combined use of inhibitors of HES6 function, androgen withdrawal and strategies for gene re-expression, would synergise in preventing the growth of castration-sensitive prostate cancer. This evidence concerns the gene HES6 and prostate carcinoma.